The Growing Role of Hospital Laboratories in Pharmaceutical Research

Hospital laboratories have traditionally been regarded as service departments. Samples are received from the wards and clinics, analysed against agreed turnaround times and reported back to clinicians, and the work is judged largely on accuracy and speed. That description remains accurate, but it no longer captures the whole picture, since a growing share of laboratory activity now supports the development of new medicines as well as the care of current patients.

The shift has been gradual and is easy to overlook from outside the laboratory. It is, however, changing the skills that laboratories need, the quality systems they operate and the relationships they hold with pharmaceutical sponsors, and for this reason it deserves more attention at board and management level than it usually receives.

From routine testing to research partner

Pharmaceutical research depends on reliable laboratory data long before patient trials begin. In early laboratory investigations involving peptides, independent testing of research peptides helps establish the purity and molecular identity of compounds used in vitro. Clinical trials then depend on laboratory measurements at almost every stage.
 
Eligibility is often confirmed through blood results or tissue analysis, safety is monitored through regular haematology and biochemistry panels, and pharmacokinetic samples have to be collected, centrifuged, separated and frozen within strict time windows so that drug levels can be measured reliably. While some of this work is sent to central laboratories contracted by the sponsor, a considerable amount still has to be handled on site, particularly where samples are unstable or results are needed quickly to guide dosing.

The scale of trial activity explains why this matters. ClinicalTrials.gov now lists close to 600,000 registered studies with locations in more than 220 countries and territories, and a large proportion of those studies rely on hospital sites to recruit patients and process their samples. In the case of a busy teaching hospital, the laboratory may be supporting dozens of active protocols at once, each with its own sampling schedule, kit requirements and shipping instructions. Transport adds a further layer of responsibility, as trial specimens sent to central laboratories are generally shipped as Biological Substance, Category B (UN 3373), which requires trained staff, compliant packaging and careful coordination with couriers.

Biomarkers and companion diagnostics

The rise of targeted therapies has placed laboratories even closer to the centre of drug development. According to the Personalized Medicine Coalition, personalised medicines accounted for roughly 36% of the new therapeutic molecular entities approved by the FDA in 2025, and for more than a third of such approvals in each of the past six years. Each of these medicines depends on a test that identifies which patients are likely to benefit.

That dependence works in both directions. During development, molecular pathology and genomics laboratories identify patients whose tumours or genetic profiles match a trial's entry criteria, and the speed of that testing has a direct effect on how quickly a study can enrol. Once a medicine is approved, the same laboratories are usually expected to offer the associated test as part of routine care, which means that validation, staffing and reimbursement have to be planned well before the drug reaches the market.

Biobanks and real-world data

Many hospitals now hold large collections of stored samples, linked to clinical records and collected with appropriate consent. These biobanks are of considerable value to pharmaceutical researchers, as they allow potential drug targets and biomarkers to be studied in real patient populations without the cost and delay of collecting new material.

Their value depends heavily on the quality of the information attached to each sample. A specimen whose collection time, storage temperature or clinical context is uncertain is of limited use to researchers, whereas one that is properly documented and linked to outcomes can support years of investigation. Long-term storage in ultra-low temperature freezers also carries running costs, including monitoring, backup power and replacement equipment, and these costs are best recognised in budgets from the outset. Integration between the laboratory information system and the wider hospital information system is therefore an important part of research readiness, alongside clear governance on consent, ethics approval and data protection.

Quality systems that research demands

Research work raises the bar for laboratory quality in several ways. Accreditation to ISO 15189:2022, the current international standard for medical laboratories, provides a strong foundation, and laboratories accredited to the earlier edition were expected to complete their transition by December 2025. Sponsors, however, will often look beyond accreditation to the specific controls applied to trial samples, including chain-of-custody records, temperature logs, equipment calibration and audit trails.

Laboratories that process trial samples should also expect sponsor audits and, in some cases, regulatory inspections. It is advisable to treat this as a routine part of research activity, with documented procedures for trial work, named staff responsible for each protocol and records that can be retrieved quickly when requested. The most recent revision of the international guideline on Good Clinical Practice, finalised in 2025, places greater emphasis on risk-based quality management, which gives well-organised laboratories an opportunity to show that their existing systems already meet much of what is expected.

Making the model work

Hospitals that benefit most from research partnerships tend to approach them deliberately. Laboratory capacity for trial work is planned and costed, so that research samples are not processed at the expense of clinical turnaround times, and contracts with sponsors cover the true cost of staff time, consumables and storage. Staff with research experience are developed internally as well as recruited, and laboratory managers are involved early in feasibility discussions for new studies, since a protocol that looks straightforward on paper may be impractical for the laboratory to support.

Handled well, the benefits extend beyond income. Patients gain earlier access to new treatments, laboratory staff develop specialist skills that improve recruitment and retention, and the hospital builds a reputation that attracts further studies. As pharmaceutical research becomes more dependent on biomarkers, real-world data and decentralised sampling, the hospital laboratory is likely to become one of the most important research assets a hospital holds.